These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2425718)

  • 1. Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis.
    Sparks DL; Markesbery WR; Slevin JT
    Ann Neurol; 1986 Jun; 19(6):602-4. PubMed ID: 2425718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease.
    Sparks DL; Hunsaker JC; Slevin JT; DeKosky ST; Kryscio RJ; Markesbery WR
    Ann Neurol; 1992 Jun; 31(6):611-20. PubMed ID: 1355334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.
    Geula C; Slevin JT
    Synapse; 1989; 4(3):248-53. PubMed ID: 2532792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of cortical somatostatin and monoamine levels in the rat does not require intact cholinergic innervation.
    Fine A; Pittaway K; de Quidt M; Czudek C; Reynolds GP
    Brain Res; 1987 Mar; 406(1-2):326-9. PubMed ID: 2436718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine transmitters and their metabolites in the basal ganglia of Huntington's disease and control postmortem brain.
    Walsh FX; Bird ED; Stevens TJ
    Adv Neurol; 1982; 35():165-9. PubMed ID: 6183949
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence for the existence of serotonin type-2 receptors on cholinergic terminals in rat cortex.
    Quirion R; Richard J; Dam TV
    Brain Res; 1985 May; 333(2):345-9. PubMed ID: 3995301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.
    Palmer AM; Wilcock GK; Esiri MM; Francis PT; Bowen DM
    Brain Res; 1987 Jan; 401(2):231-8. PubMed ID: 2434191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study.
    Rogers JD; Brogan D; Mirra SS
    Ann Neurol; 1985 Feb; 17(2):163-70. PubMed ID: 3883886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
    Ruberg M; Javoy-Agid F; Hirsch E; Scatton B; LHeureux R; Hauw JJ; Duyckaerts C; Gray F; Morel-Maroger A; Rascol A
    Ann Neurol; 1985 Nov; 18(5):523-9. PubMed ID: 3000280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alzheimer's disease and Meynert's nucleus basalis. An anatomo- clinical point of view].
    Brion S; Plas J; Massé G
    Encephale; 1986; 12(3):111-4. PubMed ID: 3769856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional distribution of monoamines and their metabolites in the human brain.
    Mackay AV; Yates CM; Wright A; Hamilton P; Davies P
    J Neurochem; 1978 Apr; 30(4):841-8. PubMed ID: 650225
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI.
    Teipel SJ; Flatz WH; Heinsen H; Bokde AL; Schoenberg SO; Stöckel S; Dietrich O; Reiser MF; Möller HJ; Hampel H
    Brain; 2005 Nov; 128(Pt 11):2626-44. PubMed ID: 16014654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
    Beal MF; MacGarvey U; Swartz KJ
    Ann Neurol; 1990 Aug; 28(2):157-61. PubMed ID: 1699471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.
    Palmer AM; Stratmann GC; Procter AW; Bowen DM
    Ann Neurol; 1988 Jun; 23(6):616-20. PubMed ID: 2457353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of the nucleus basalis in Down's syndrome.
    Casanova MF; Walker LC; Whitehouse PJ; Price DL
    Ann Neurol; 1985 Sep; 18(3):310-3. PubMed ID: 2932050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seasonal and circadian monoamine variations in human brains examined post mortem.
    Carlsson A; Svennerholm L; Winblad B
    Acta Psychiatr Scand Suppl; 1980; 280():75-85. PubMed ID: 6157305
    [No Abstract]   [Full Text] [Related]  

  • 17. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease.
    Nakano I; Hirano A
    Ann Neurol; 1984 May; 15(5):415-8. PubMed ID: 6732189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biogenic amines distribution in the brain of nervous and normal pointer dogs. A genetic animal model of anxiety.
    Gurguis GN; Klein E; Mefford IN; Uhde TW
    Neuropsychopharmacology; 1990 Aug; 3(4):297-303. PubMed ID: 1698064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease.
    Whitehouse PJ
    Adv Neurol; 1987; 45():393-7. PubMed ID: 2881448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.